D-VRd Improves MRD-Negativity Rates vs VRd in Newly Diagnosed, Transplant-Eligible Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 60
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 14
Results: 15
1
2
Valemetostat Tosilate Demonstrates Clinically Meaningful Efficacy in R/R PTCL.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 58
- By:
- Publication type:
- Article
3
Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 54
- By:
- Publication type:
- Article
4
Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2- Gastric/GEJ Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 50
- By:
- Publication type:
- Article
5
Beyond Patient Engagement: How to Effectively Partner With Patients to Optimize Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 49
- By:
- Publication type:
- Article
6
Personalized Initiatives Empower Patients to Actively Participate in Cancer Research.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 48
- By:
- Publication type:
- Article
7
Mesenchymal Stromal Cells Could Serve as Preventive Therapy for Chronic Radiation-Induced Dry Mouth.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 42
- By:
- Publication type:
- Article
8
BRIA-ABC Trial Explores Novel Post-ADC Strategy for Metastatic Breast Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 34
- By:
- Publication type:
- Article
9
MAGEA4 Opens the Door for Engineered Cellular Therapies in Solid Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 31
- By:
- Publication type:
- Article
10
Brahmer's Take: Advancements in 3 Cornerstone Settings of NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 24
- By:
- Publication type:
- Article
11
Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 16
- By:
- Publication type:
- Article
12
Amivantamab/Lazertinib Approval Builds Upon First-Line TKI Use in EGFR+ NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 10
- By:
- Publication type:
- Article
13
FDA Digest.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 8
- Publication type:
- Article
14
A Call to Action: Determining Optimal Dose, Schedule, and Appropriate Modifications for Antineoplastic Pharmaceutical Agents.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 6
- By:
- Publication type:
- Article
15
New Tumor-Agnostic and Targeted Regimens Instill Hope for the Future of Cancer Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 14, p. 4
- By:
- Publication type:
- Article